Latest Breaking News On - Universal registration document - Page 1 : comparemela.com

Ipsen s Iqirvo® receives U S FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis | Company Announcement

Ipsen s Iqirvo® receives U S FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis | Company Announcement
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

United statesFrance generalUnited kingdomHong kongIpsen euronextClin gastroenterol hepatolCarol robertsChristelle huguetAnna gibbinsIpsen iqirvoRachel reiffKris kowdleyNicolas boglerAmy wolfLiver instituteIpsen pharmaceuticals inc

Ipsen Pharma: Ipsen s Iqirvo® receives U S FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Iqirvo® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver

France generalUnited statesUnited kingdomHong kongChristelle huguetRachel reiffKris kowdleyNicolas boglerAnna gibbinsAmy wolfCarol robertsClin gastroenterol hepatolIpsen euronextIpsen pharmaceuticals incRegulatory agencyLiver institute

Ipsen s Iqirvo® receives U S FDA accelerated approval as a

Ipsen s Iqirvo® receives U S FDA accelerated approval as a
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

France generalUnited statesHong kongUnited kingdomCarol robertsAnna gibbinsRachel reiffIpsen euronextClin gastroenterol hepatolNicolas boglerAmy wolfChristelle huguetKris kowdleyEuropean medicines agencyIpsen pharmaceuticals incFibrotic liver disease consortium investigators

Clariane: Information on the Availability of an Amendment to the 2023 Universal Registration Document

Regulatory News: Clariane (Paris:CLARI) (CLARIA.PA ISIN FR0010386334), Europe's leading community for care in times of vulnerability (the "Company"), announces that an amendment (the "Amendment")

Champagne ardenneFrance generalUnited statesFlorian bacheletJulie maryCommunity careNeither the companyClariane universityCompany europeanRegulatory newsRegistration documentGeneral meetingTerm careSpecialized careStrenghtening planInvestor relations

Clariane: Information relating to the availability of a prospectus approved by the Autorité des marchés financiers under number 24-191

Regulatory News: NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN. THIS COMMUNICATION IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES OF AMERICA OR ANY

Champagne ardenneFrance generalUnited kingdomUnited statesFlorian bacheletLeima valeursJulie maryNeither the companyAker holdingEuropean parliamentGp recovery fundFooted seriesFinancial servicesHolding malakoff humanisRegulatory newsReserved capital increase